Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 6Completed 6Active not recruiting 4Unknown 3Terminated 2Withdrawn 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

E 7107 2Carboplatin 2palbociclib 1gedatolisib 1eniluracil 1dabrafenib 1abarelix 1Topotecan 1Standard of Care 1Radionuclide Imaging 1Radiofrequency Ablation 1Practice Guidelines as Topic 1Positron-Emission Tomography 1Passive Cutaneous Anaphylaxis 1Paclitaxel 1NUC-1031 1Morphine 1Methadone 1Maltose 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1KB004 1Injections 1Infusions, Parenteral 1Hyperthermic Intraperitoneal Chemotherapy 1Hydromorphone 1Gemcitabine 1Fluorodeoxyglucose F18 1Flucytosine 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Neoplasms × palbociclib × Clear all
NCT03065062 2026-02-13

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Suspended
75 enrolled
GastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡